Inventor · Steamboat Springs, CO, US

Julia Grigorieva

23Patents
8h-index
12Co-inventors
68Inventor score

Filing activity: Mar 31, 2006 → Dec 11, 2020

Most-cited inventions

PatentTitleAreaCited byStatus
US7736905B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 47 Active
US7879620B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 19 Active
US7858389B2 Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway Emerging Cross-Sectional Technologies 19 Active
US7858390B2 Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway Emerging Cross-Sectional Technologies 17 Active
US7906342B2 Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 16 Active
US7867775B2 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway Emerging Cross-Sectional Technologies 15 Active
US8097469B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 14 Active
US8718996B2 Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents Emerging Cross-Sectional Technologies 11 Active
US8914238B2 Method for predicting breast cancer patient response to endocrine therapy Electricity 7 Active
US8119418B2 Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 6 Active
US8119417B2 Monitoring treatment of head and neck cancer patients with drugs EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 6 Active
US9824182B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 6 Active
US10007766B2 Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods Physics 5 Active
US9152758B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 4 Active
US9254120B2 Method for predicting breast cancer patient response to combination therapy Electricity 4 Active
US8586380B2 Monitoring treatment of head and neck cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 4 Active
US8586379B2 Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 4 Active
US10217620B2 Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry Emerging Cross-Sectional Technologies 4 Active
US10037874B2 Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry Emerging Cross-Sectional Technologies 4 Active
US12230398B2 Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods Physics 0 Active
US10950348B2 Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods Physics 0 Active
US11150238B2 Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups Physics 0 Active
US11621057B2 Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy Physics 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.